Visionary Holdings' Visionary Health Technology Group Appoints Wenxuan Cai As GV Hong Kong CEO; Launches Subsidiary In Nanjing, China

Benzinga · 12/30/2025 14:32

Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (NASDAQ:GV), today announced that its wholly owned subsidiary, Visionary Health Technology Group Limited("GV Hong Kong", has official appointed Ms. Wenxuan Cai as Chief Executive Officer of GV Hong Kong, effective immediately.

In parallel, the GV Hong Kong has established a new wholly owned subsidiary in Nanjing, China, dedicated primarily to sales execution and market development. This milestone marks GV's formal transition from strategic positioning to active on-the-ground revenue generation.

Strengthening Leadership to Drive Market Execution

Ms. Cai joins the Company with nearly two decades of extensive experience in market expansion, brand commercialization, and building sales organization across healthcare and enterprise management sectors. She possesses a deep understanding of China's premium healthcare market and a proven history of translating high-level strategy into scalable sales outcomes.

As CEO of GV Hong Kong, Ms. Cai will focus on:

  • Building and leading regional sales and marketing teams;
  • Executing go-to-market strategies for GV's offerings in the fields of cellular rejuvenation and aesthetic treatment;
  • Expanding institutional, channel, and strategic partnerships;
  • Driving sustainable revenue growth and enhancing sales visibility.

Sales Infrastructure Now Fully Deployed

The newly established Nanjing entity will serve as frontline commercial platforms, handling regional sales operations and channel development. Combined with GV's Asia-Pacific platform in Hong Kong, the Company has completed a fully integrated commercial structure spanning strategy, products, and sales execution. This development signals that GV's commercialization efforts are now actively operational and scalable.